In Brief: Wright Medical
This article was originally published in The Gray Sheet
Executive SummaryWright Medical: Enters an exclusive worldwide license agreement with Parteq Research and Development Innovations for the manufacture and distribution of the Questor Elbow System. The Questor system is one of two available systems offering a radial head component, Wright says, a feature that is "critical for maintaining normal joint function, and a significant anatomical representation of the elbow joint." The deal, terms of which were not disclosed, "furthers Wright's expansion in small joint and upper extremity orthopedics"...
You may also be interested in...
Attorneys say Sarepta did not have an obligation to report its appeal, particularly since winning a formal dispute filing with the US FDA is a long shot.
Sarepta’s Vyondys: Renal Toxicity Concerns That Delayed Approval Get Enhanced Postmarketing Scrutiny, Label Warning
Sarepta must perform enhanced pharmacovigilance for serious renal toxicity events and rhabdomyolysis with the Duchenne muscular dystrophy drug, which carries a label warning for renal toxicity. Approval letter includes 2024 target completion date for ESSENCE confirmatory trial.
Efficacy data were striking to committee members, but they want to ensure postmarketing plans gather adequate data to address safety questions.